EUVIMEDEUVIMED entdecken
Open Access

Antitumor activities of a defucosylated anti‑EpCAM monoclonal antibody in colorectal carcinoma xenograft models

Guanjie Li, Hiroyuki Suzuki, Tomokazu Ohishi, Teizo Asano, Tomohiro Tanaka, Miyuki Yanaka, Takuro Nakamura, Takeo Yoshikawa, Manabu Kawada, Mika K Kaneko, Yukinari Kato

International Journal of Molecular Medicine · 2023

DOI: 10.3892/ijmm.2023.5221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Medicine, 2023. Verfasst von Guanjie Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980‑8575, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Colorectal Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epithelial cell adhesion molecule (EpCAM) is a type I transmembrane glycoprotein, which is highly expressed on tumor cells. As EpCAM plays a crucial role in cell adhesion, survival, proliferation, stemness, and tumorigenesis, it has been considered as a promising target for tumor diagnosis and therapy. Anti‑EpCAM monoclonal antibodies (mAbs) have been developed and have previously demonstrated promising outcomes in several clinical trials. An anti‑EpCAM mAb, EpMab‑37 (mouse IgG1, kappa) was previously developed by the authors, using the cell‑based immunization and screening method. In the present study, a defucosylated version of anti‑EpCAM mAb (EpMab‑37‑mG2a‑f) was generated to evaluate the antitumor activity against EpCAM‑positive cells. EpMab‑37‑mG2a‑f recognized EpCAM‑overexpressing CHO‑K1 (CHO/EpCAM) cells with a moderate binding‑affinity [dissociation constant (KD)=2.2x10‑8 M] using flow cytometry. EpMab‑37‑mG2a‑f exhibited potent antibody‑dependent cellular cytotoxicity (ADCC) and complement‑dependent cytotoxicity (CDC) for CHO/EpCAM cells by murine splenocytes and complements, respectively. Furthermore, the administration of EpMab‑37‑mG2a‑f significantly suppressed CHO/EpCAM xenograft tumor development compared with the control mouse IgG. EpMab‑37‑mG2a‑f also exhibited a moderate binding‑affinity (KD=1.5x10‑8 M) and high ADCC and CDC activities for a colorectal cancer cell line (Caco‑2 cells). The administration of EpMab‑37‑mG2a‑f to Caco‑2 tumor‑bearing mice significantly suppressed tumor development compared with the control. By contrast, EpMab‑37‑mG2a‑f never suppressed the xenograft tumor growth of Caco‑2 cells in which EpCAM was knocked out. On the whole, these results indicate that EpMab‑37‑mG2a‑f may exert antitumor activities against EpCAM‑positive cancers and may thus be a promising therapeutic regimen for colorectal cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalColorectal NeoplasmsCricetinaeHumansAnimalsMiceCaco-2 CellsHeterograftsEpithelial Cell Adhesion MoleculeCricetulusImmunoglobulin GXenograft Model Antitumor AssaysCell Line, Tumor

Stichwörter der Autor:innen

ADCCCDCEpCAM monoclonal antibodycolorectal cancer

Substanzen

Antibodies, MonoclonalEpithelial Cell Adhesion MoleculeImmunoglobulin G

Autor:innen und Institutionen

  • Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980‑8575, Japan.
  • Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Research Foundation, Numazu, Shizuoka 410‑0301, Japan.
  • Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980‑8575, Japan.
  • Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980‑8575, Japan.

Zitieren

APA

Li, G., Suzuki, H., Ohishi, T., Asano, T., Tanaka, T., Yanaka, M., Nakamura, T., Yoshikawa, T., Kawada, M., Kaneko, M. K., & Kato, Y. (2023). Antitumor activities of a defucosylated anti‑EpCAM monoclonal antibody in colorectal carcinoma xenograft models. International Journal of Molecular Medicine. https://doi.org/10.3892/ijmm.2023.5221

Vancouver

Li G, Suzuki H, Ohishi T, Asano T, Tanaka T, Yanaka M, et al. Antitumor activities of a defucosylated anti‑EpCAM monoclonal antibody in colorectal carcinoma xenograft models. International Journal of Molecular Medicine. 2023. doi:10.3892/ijmm.2023.5221

BibTeX
@article{Li2023,
  author = {Li, Guanjie and Suzuki, Hiroyuki and Ohishi, Tomokazu and Asano, Teizo and Tanaka, Tomohiro and Yanaka, Miyuki and Nakamura, Takuro and Yoshikawa, Takeo and Kawada, Manabu and Kaneko, Mika K and Kato, Yukinari},
  title = {Antitumor activities of a defucosylated anti‑EpCAM monoclonal antibody in colorectal carcinoma xenograft models},
  journal = {International Journal of Molecular Medicine},
  year = {2023},
  doi = {10.3892/ijmm.2023.5221}
}
Kostenlos starten →